{"id":"gd2","name":"GD2 (disialoganglioside)","symbol":"GD2 (B4GALNT1 product)","route":"/targets/gd2/","asOf":"2026-09-07","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4117","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135454","uniprot":"https://www.uniprot.org/uniprotkb/Q00973/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q00973","open-targets":"https://platform.opentargets.org/target/ENSG00000135454","civic":"https://civicdb.org/genes/2583/summary","oncokb":"https://www.oncokb.org/gene/B4GALNT1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=B4GALNT1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=B4GALNT1","depmap":"https://depmap.org/portal/gene/B4GALNT1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000135454-B4GALNT1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2583","omim":"https://www.omim.org/entry/601873"}],"products":[{"id":"dinutuximab","name":"Dinutuximab (ch14.18) / dinutuximab beta","status":"approved","modality":"Monoclonal antibody (anti-GD2, chimeric)","route":"/drugs/dinutuximab/"},{"id":"naxitamab","name":"Naxitamab","status":"approved","modality":"Monoclonal antibody (anti-GD2, humanised)","route":"/drugs/naxitamab/"}],"trials":[{"id":"hr-nbl1","name":"SIOPEN HR-NBL1","nct":"NCT01704716","phase":"3","status":"mixed"},{"id":"anbl0032","name":"COG ANBL0032","nct":"NCT00026312","phase":"3","status":"positive"},{"id":"nct04221035","name":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","nct":"NCT04221035","phase":"3","status":"recruiting"},{"id":"anbl17p1","name":"ANBL17P1","nct":"NCT03786783","phase":"2","status":"positive"},{"id":"naxitamab-201","name":"Naxitamab Study 201","nct":"NCT03363373","phase":"2","status":"positive"},{"id":"anbl1221","name":"ANBL1221","nct":"NCT01767194","phase":"2","status":"positive"},{"id":"gd2-cart01","name":"GD2-CART01 (Bambino Gesù phase 1/2)","nct":"NCT03373097","phase":"1/2","status":"positive"},{"id":"nct07744256","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","nct":"NCT07744256","phase":"1/2","status":"recruiting"},{"id":"nct07480213","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","nct":"NCT07480213","phase":"1/2","status":"recruiting"},{"id":"nct07011654","name":"Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)","nct":"NCT07011654","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["united-therapeutics","y-mabs"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}